A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).

MLA

Pulsipher, Michael A., et al. “A Phase I/II Study of the Safety and Efficacy of the Addition of Sirolimus to Tacrolimus/Methotrexate Graft versus Host Disease Prophylaxis after Allogeneic Haematopoietic Cell Transplantation in Paediatric Acute Lymphoblastic Leukaemia (ALL).” British Journal of Haematology, vol. 147, no. 5, Dec. 2009, pp. 691–99. EBSCOhost, https://doi.org/10.1111/j.1365-2141.2009.07889.x.

APA

Pulsipher, M. A., Wall, D. A., Grimley, M., Goyal, R. K., Boucher, K. M., Hankins, P., Grupp, S. A., & Bunin, N. (2009). A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). British Journal of Haematology, 147(5), 691–699. https://doi.org/10.1111/j.1365-2141.2009.07889.x

Chicago

Pulsipher, Michael A, Donna A Wall, Michael Grimley, Rakesh K Goyal, Kenneth M Boucher, Patricia Hankins, Stephan A Grupp, and Nancy Bunin. 2009. “A Phase I/II Study of the Safety and Efficacy of the Addition of Sirolimus to Tacrolimus/Methotrexate Graft versus Host Disease Prophylaxis after Allogeneic Haematopoietic Cell Transplantation in Paediatric Acute Lymphoblastic Leukaemia (ALL).” British Journal of Haematology 147 (5): 691–99. doi:10.1111/j.1365-2141.2009.07889.x.